[go: up one dir, main page]

CY1115803T1 - Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα - Google Patents

Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα

Info

Publication number
CY1115803T1
CY1115803T1 CY20141101015T CY141101015T CY1115803T1 CY 1115803 T1 CY1115803 T1 CY 1115803T1 CY 20141101015 T CY20141101015 T CY 20141101015T CY 141101015 T CY141101015 T CY 141101015T CY 1115803 T1 CY1115803 T1 CY 1115803T1
Authority
CY
Cyprus
Prior art keywords
methods
vulnerable
measures
action
cellular immune
Prior art date
Application number
CY20141101015T
Other languages
English (en)
Inventor
Jirina Bartunková
Radek Spísek
Original Assignee
SOTIO a.s.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11172622A external-priority patent/EP2543386A1/en
Application filed by SOTIO a.s. filed Critical SOTIO a.s.
Publication of CY1115803T1 publication Critical patent/CY1115803T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Φέρονται στο προσκήνιο φαρμακευτικές συνθέσεις προς επαγωγή μίας ανοσοποιητικής απόκρισης έναντι κυττάρων όγκου οι οποίες συνθέσεις περιλαμβάνουν κύτταρα όγκου τα οποία καθίστανται αποπτωτικά μέσω κατεργασίας υπό μεγάλη υδροστατική πίεση και δενδριτικά κύτταρα, καθώς και μέθοδοι παραγωγής τέτοιων συνθέσεων.
CY20141101015T 2011-07-05 2014-12-05 Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα CY1115803T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504387P 2011-07-05 2011-07-05
EP11172622A EP2543386A1 (en) 2011-07-05 2011-07-05 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
EP12734884.5A EP2691110B1 (en) 2011-07-05 2012-07-04 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Publications (1)

Publication Number Publication Date
CY1115803T1 true CY1115803T1 (el) 2017-01-25

Family

ID=50023029

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141101015T CY1115803T1 (el) 2011-07-05 2014-12-05 Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα

Country Status (7)

Country Link
JP (1) JP6235085B2 (el)
CL (1) CL2013003282A1 (el)
CY (1) CY1115803T1 (el)
HR (1) HRP20141230T1 (el)
IL (2) IL229702A (el)
MX (1) MX2013013243A (el)
ZA (1) ZA201307886B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107058101B (zh) 2011-10-17 2021-06-01 麻省理工学院 细胞内传递
KR102386122B1 (ko) 2013-08-16 2022-04-14 메사추세츠 인스티튜트 오브 테크놀로지 세포로의 선택적 물질 전달
CA2964392A1 (en) 2014-10-31 2016-05-06 Massachussetts Institute Of Technology Delivery of biomolecules to immune cells
CA2964138C (en) 2014-11-14 2023-11-14 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
CA2988996A1 (en) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Delivery of materials to anucleate cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases

Also Published As

Publication number Publication date
MX2013013243A (es) 2014-05-30
CL2013003282A1 (es) 2014-10-10
HRP20141230T1 (hr) 2015-02-13
IL229702A (en) 2016-09-29
IL247781A0 (en) 2016-11-30
IL229702A0 (en) 2014-01-30
ZA201307886B (en) 2015-03-25
JP2017025066A (ja) 2017-02-02
IL247781B (en) 2019-11-28
JP6235085B2 (ja) 2017-11-22

Similar Documents

Publication Publication Date Title
PH12013502462B1 (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
PH12019501959A1 (en) Therapeutic rna
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
WO2014018563A3 (en) Methods for the treatment of cancer
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
PH12017500296B1 (en) Anti-tigit antibodies
EA201400178A1 (ru) Лечение рака молочной железы
EA201291194A1 (ru) Индолы
CY1115803T1 (el) Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα
MY195167A (en) Modified Nucleotide Linkers
HK1245080A1 (zh) 自然杀伤细胞的方法和组合物
MX391015B (es) Composiciones de nanoparticulas y usos de las mismas
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
NZ739133A (en) Cellular targeted active ingredient delivery system
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
MX2018002318A (es) Proceso mejorado para producir fucoxantina y/o polisacaridos de microalgas.
EP4552698A3 (en) Methods of treating prostate cancer
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
EP3998341A3 (en) Adenoviral vectors
EA201891601A1 (ru) Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
RU2012151073A (ru) Способ стабилизации раствора дигидрокверцетина
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
TH149241A (th) วิถีทาง และวิธีสำหรับแอคทีฟ เซลลูลาร์ อิมมูโนเธราปี เพื่อรักษาโรคมะเร็งโดยการใช้เซลล์เนื้องอกซึ่งถูกฆ่าโดยแรงดันไฮโดรสแทติคระดับสูง และเซลล์เดนไดรท์
CY1118614T1 (el) Νεα παραγωγα (αζα)βενζυδρυλαιθερα, διεργασια παρασκευης τους και χρηση τους ως προσδετες h4-υποδοχεα για θεραπευτικες εφαρμογες